Journal of Clinical Oncology · 2003 · 176 citations · 34 references
MedicineOncologyRadiation OncologyClinical Radiation OncologyHematologic OncologyRadiation DosimetryLymphoid NeoplasmsLymphoid TumorsRadiation TherapyResponse AssessmentTherapy Response AssessmentComplete Response AssessmentExtranodal Marginal Zone LymphomaLocal Disease ProgressionLocal Tumor ProgressionLymphoma RelapseLymphoma Treatment ResponsePartial Response Assessment
PURPOSE: To study the response rates and duration of response after low-dose (4 Gy) involved field radiotherapy (LD-IF-RT) in patients with recurrent indolent lymphoma. PATIENTS AND METHODS: A total of 109 assessable patients (304 symptomatic sites) were irradiated (53 males and 56 females; median age, 62 years; range, 35 to 93), including 98 patients with follicular lymphoma (43 grade 1 and 55 grade 2), nine extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue-type and two patients with lymphoplasmacytoid lymphoma. Bulky disease (> or =5 cm) was present in 52% of all patients. A median of two prior regimens (range, 0 to 11) preceded LD-IF-RT. The median time since diagnosis was 41 months (range, 2 to 358 months). Time to (local) progression was calculated according to the Kaplan-Meier method. Differences in response rates between treatments within the same patient were compared using the McNemar test. RESULTS: The overall response rate was 92%; complete response was reached in 67 patients (61%), partial response in 34 patients (31%), stable disease in six patients (6%), and progressive disease in two patients (2%). The median time to progression was 14 months. The median time to local progression was 25 months. The 67 patients with complete response showed a median time to progression of 25 months and a median time to local progression of 42 months. None of the factors studied (age, sex, follicular lymphoma grade, radiotherapy regimen, number of previous regimens and previous history, number of positive sites or largest lymphoma diameter) were found to be related to response rate. CONCLUSION: LD-IF-RT is a valuable asset in the management of patients with follicular lymphoma and should be considered in patients with recurrent disease.
34
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
New England Journal of Medicine · 1993 · 5K citations · Full text
Medicine, Oncology, Chemotherapy +15
Izidore S. Lossos, Ash A. Alizadeh, Maximilian Diehn et al. · Proceedings of the National Academy of Sciences · 2002 · 226 citations · Full text
The rise in incidence of lymphomas in Europe 1985–1992
R. Cartwright, H Brincker, Paule‐Marie Carli et al. · European Journal of Cancer · 1999 · 184 citations
Role of radiation therapy in localized non-Hodgkin's lymphoma
Simon Sutcliffe, Mary Gospodarowicz, R. S. Bush et al. · Radiotherapy and Oncology · 1985 · 156 citations